Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): Clinical characteristics. Background: Physical activity (PA), in particular longer duration or higher intensity, may ...
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...
First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). This ...
Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results